Therapeutic effect of Colla corii asini on gut microbiota dysbiosis of patients with primary hepatic carcinoma after TACE and TAE

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200055892

Enrollment

Unknown

Registered

2022-01-22

Start date

2017-07-01

Completion date

Unknown

Last updated

2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary hepatocellular carcinoma

Interventions

Experimental group:Take Colla corii asini during TACE/TAE

Control group:Treatment with TACE/TAE is performed only

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age > 18; 2. Meet diagnostic criteria for primary liver cancer with hepatitis B; 3. Meet TACE treatment indications for primary liver cancer; 4. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe diarrhea, enema operation, antibiotics, lactose or microecological preparations in nearly 2 weeks; 2. Severely infected with disease; 3. Patients with incomplete heart, lung, liver and kidney function.

Design outcomes

Primary

Measure	Time frame
Bacteroidetes;Firmicutes;Proteobacteria;Fusobacteria;Actinobacteria;Cyanobacteria;Verrucomicrobia;Tenericutes;Synergistetes;Saccharibacteria;	—

Countries

China

Contacts

Public ContactZhang Bo

Shandong Cancer Hospital and Institute

zhangbo2006@163.com+86 13355313206

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026